Selank Reviews

Primary Sources

References and primary source citations

All citations are to peer-reviewed publications, conference proceedings, and registered scientific reviews. PubMed IDs and DOIs are provided where available.

Read the research brief

Primary citations

The citations below are the complete reference set for all claims made on this site. References are numbered in the order they first appear across the site's pages. Each entry includes authors, journal, year, and direct links to the primary record where publicly accessible.

For questions about the editorial methodology and source selection criteria, see the About page.

Filtering by mechanism, species, or year is available via the table controls on this page.

  1. Vyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein & Peptide Letters. 2018;25(10):914-923. ↗
  2. Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001;131(4):315-317. ↗
  3. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences. 2008;421:241-243. ↗
  4. Kolik LG, Nadorova AV, Antipova TA, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of Experimental Biology and Medicine. 2019;167(5):641-644. ↗
  5. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017;2017:5091027. ↗
  6. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. ↗
  7. Syunyakov T, Teleshova ES, Neznamov GG, Bochkarev VK. Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic Selank. European Psychiatry. 2012;27(S1), abstract P-1114. ↗
  8. Konstantinopolsky MA, Chernyakova IV, Kolik LG. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of Experimental Biology and Medicine. 2022;174(2):174-179. ↗
  9. Kolik LG, Nadorova AV, Kozlovskaya MM. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bulletin of Experimental Biology and Medicine. 2014;157(1):52-55. ↗
  10. Yasenyavskaya AL, Samotrueva MA, Tsibizova AA, et al. The Influence of Selank on the Level of Cytokines Under the Conditions of 'Social' Stress. Current Reviews in Clinical and Experimental Pharmacology. 2021;16(2):162-167. ↗
  11. Filatova E, Kasian A, Kolomin T, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017;8:89. ↗
  12. Vasil'eva EV, Kondrakhin EA, Salimov RM, Kovalev GI. Comparison of pharmacological effects of heptapeptide Selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice. Eksperimental'naia i Klinicheskaia Farmakologiia. 2016;79(9):3-11. ↗
  13. Kozlovskii II, Andreeva LA, Kozlovskaia MM, Nadorova AV, Kolik LG. The role of opioid system in peculiarities of anti-anxiety effect of peptide anxiolytic Selank. Eksperimental'naia i Klinicheskaia Farmakologiia. 2012;75(2):10-13. ↗
  14. Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. Experimental optimization of learning and memory processes by Selank. Eksperimental'naia i Klinicheskaia Farmakologiia. 2010;73(8):2-5. ↗
  15. Narkevich VB, Kudrin VS, Klodt PM, et al. Effects of heptapeptide Selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study. Eksperimental'naia i Klinicheskaia Farmakologiia. 2008;71(5):8-12. ↗
  16. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. ↗
  17. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. ↗
  18. Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and Behavioral Physiology. 2003;33(9):853-860. ↗
  19. Monis A, Maple K. Selank Medical Evidence Review. Medical Anti-Aging. August 2024. ↗
  20. Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. ↗
  21. Fomenko EV, Bobyntsev II, Kryukov AA, et al. Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Immobilization Stress. Bulletin of Experimental Biology and Medicine. 2017;163(4):415-418. ↗